Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial

scientific article published on 30 April 2014

Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/HED.23655
P698PubMed publication ID24595923

P2093author name stringAlexandra Kaider
Christoph Arnoldner
Dominik Riss
Martin Burian
Axel Wolf
Veronika Kranebitter
P2860cites workThe effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasiaQ33405788
Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).Q33897059
Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the noseQ34260695
Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxisQ37846178
Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxisQ37846182
Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapyQ37965478
An epistaxis severity score for hereditary hemorrhagic telangiectasiaQ48906632
Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumabQ79811356
P433issue6
P921main subjecthereditary hemorrhagic telangiectasiaQ776881
placebo-controlled trialQ108853737
placeboQ269829
bevacizumabQ413299
P304page(s)783-787
P577publication date2014-04-30
P1433published inHead & NeckQ13703062
P1476titleIntranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial
P478volume37

Reverse relations

cites work (P2860)
Q35336067Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia
Q90427144Effect Of Bevacizumab On Growth Of Human Nasal Polyposis In Vitro; An Off-Label Use Of Anti-Angiogenic Agent For Nasal Polyposis Treatment
Q36821724Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study
Q27317227Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management
Q57163936Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective
Q36245169Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).
Q34388065Optimal management of hereditary hemorrhagic telangiectasia
Q64898571Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia.
Q38374758Pericytes as targets in hereditary hemorrhagic telangiectasia.
Q92421283Pericytes in Hereditary Hemorrhagic Telangiectasia
Q92271765Risk factors for hemorrhage of brain arteriovenous malformation
Q36416717Technique modifications for septodermoplasty: an illustrative case
Q42279034Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report.

Search more.